16th week of 2014 patent applcation highlights part 53 |
Patent application number | Title | Published |
20140107016 | Methods for Treating HCV - The present invention features interferon- and ribavirin-free therapies for the treatment of HCV. Preferably, the treatment is over a shorter duration of treatment, such as no more than 12 weeks. In one aspect, the therapies comprise administering at least two direct acting antiviral agents without interferon and ribavirin to a subject with HCV infection. For example, the therapies comprise administering to a subject an effective amounts of therapeutic agent 1, therapeutic agent 2 (or therapeutic agent 3), and an inhibitor of cytochrome P450 (e.g., ritonavir). | 2014-04-17 |
20140107017 | Methods for Treating HCV - The present invention features interferon-free therapies for the treatment of HCV. Preferably, the treatment is over a shorter duration, such as no more than 12 weeks. In one aspect, the therapies comprise administering at least two direct acting antiviral agents and ribavirin to a subject with HCV infection. For example, the therapies comprise administering to the subject effective amounts of therapeutic agent 1, therapeutic agent 2 (or therapeutic agent 3), an inhibitor of cytochrome P450 (e.g., ritonavir), and ribavirin. | 2014-04-17 |
20140107018 | ANTICANCER AND ANTI-OBESITY CYCLIC PEPTIDE AGENTS - A compound having formula (I) or formula (II): | 2014-04-17 |
20140107019 | ENGINEERED POLYPEPTIDES HAVING ENHANCED DURATION OF ACTION - Compounds are provided having inter alia good duration of action, high potency and/or convenient dosing regimens including oral administration. The compounds are engineered polypeptides which incorporate an albumin binding domain in combination with one or more biologically active polypeptides. Also provided are pharmaceutical compositions and methods of treatment for diseases and disorders including obesity and overweight, diabetes, dyslipidemia, hyperlipidemia, Alzheimer's disease, fatty liver disease, short bowel syndrome, Parkinson's disease, cardiovascular disease, and other and disorders of the central nervous system. | 2014-04-17 |
20140107020 | FIBRONECTIN BASED SCAFFOLD DOMAIN PROTEINS THAT BIND TO MYOSTATIN - The present invention relates to fibronectin-based scaffold domain proteins that bind to myostatin. The invention also relates to the use of these proteins in therapeutic applications to treat muscular dystrophy, cachexia, sarcopenia, osteoarthritis, osteoporosis, diabetes, obesity, COPD, chronic kidney disease, heart failure, myocardial infarction, and fibrosis. The invention further relates to cells comprising such proteins, polynucleotides encoding such proteins or fragments thereof, and to vectors comprising the polynucleotides encoding the proteins. | 2014-04-17 |
20140107021 | GLUCAGON ANTAGONIST-GIP AGONIST CONJUGATES AND COMPOSITIONS FOR THE TREATMENT OF METABOLIC DISORDERS AND OBESITY - Provided herein are peptide combinations comprising a GIP agonist peptide and a glucagon antagonist peptide. In some embodiments, the peptide combination is provided as a composition, e.g., a pharmaceutical composition, while in other embodiments, the peptide combination is provided as a kit. In yet other embodiments, the peptide combination is provided as a conjugate, e.g., a fusion peptide, a heterodimer. In specific aspects, the GIP agonist peptide is an analog of native human glucagon. In specific aspects, the glucagon antagonist peptide is an analog of native human glucagon. In some embodiments, the GIP agonist peptide is covalently attached to the glucagon antagonist peptide via a linker. Method of treating a disease, e.g., a metabolic disorder, such as diabetes and obesity, comprising administering the peptide compositions described herein are further provided. | 2014-04-17 |
20140107022 | CHIMERIC FIBROBLAST GROWTH FACTOR 19 PROTEINS AND METHODS OF USE - The present invention relates to a chimeric protein that includes an N-terminus coupled to a C-terminus, where the N-terminus includes a portion of a paracrine fibroblast growth factor (“FGF”) and the C-terminus includes a C-terminal portion of an FGF19 molecule. The portion of the paracrine FGF is modified to decrease binding affinity for heparin and/or heparan sulfate compared to the portion without the modification. The present invention also relates to pharmaceutical compositions including chimeric proteins according to the present invention, methods for treating a subject suffering from diabetes, obesity, or metabolic syndrome, and methods of screening for compounds with enhanced binding affinity for the βKlotho-FGF receptor complex involving the use of chimeric proteins of the present invention. | 2014-04-17 |
20140107023 | NON-PEPTIDYL POLYMER-INSULIN MULTIMER AND METHOD FOR PRODUCING THE SAME - The present invention relates to a non-peptidyl polymer-insulin multimer comprising two or more of a non-peptidyl polymer-insulin conjugate prepared by linking a non-peptidyl polymer and insulin via a covalent bond, in which the conjugates are complexed with cobalt ion to form a multimer, a method and kit for the preparation of the multimer, a pharmaceutical composition for the prevention or treatment of diabetes comprising the multimer as an active ingredient, and a method for preventing or treating diabetes by administering the composition to a subject. | 2014-04-17 |
20140107024 | Treatment of Type 2 Diabetes With FTY720 - The present disclosure provides therapeutic methods for prevention and treatment of type-2 diabetes comprising administering to the subject an effective amount of FTY720 or an analog. | 2014-04-17 |
20140107025 | OCULAR DRUG DELIVERY SYSTEM - An ocular drug delivery system including a composition in which a formulation having an active agent such as rHGH and or an rHGH mimic, e.g., that increases insulin growth factor (IGF) or that alters insulin growth factor binding protein (IGFBP) in a subject is dispersed in a pharmaceutical carrier. The composition is configured for placement in, around or on an eye of the subject, and the composition provides controlled release of an amount of the active agent to the eye effective to promote ocular surface and corneal neural regeneration and wound healing. | 2014-04-17 |
20140107026 | BONE MORPHOGENETIC PROTEINS FOR THE TREATMENT OF INSULIN RESISTANCE - The present disclosure relates to compositions and methods for treating insulin resistance and/or obesity in a cell and/or a subject | 2014-04-17 |
20140107027 | METHODS AND COMPOSITIONS FOR TREATING AMYLOID-RELATED DISEASES - Methods, compounds, pharmaceutical compositions and kits are described for treating or preventing amyloid-related disease. | 2014-04-17 |
20140107028 | METHODS AND COMPOSITIONS FOR PREDICTING RESPONSE TO GLP-1 ANALOGS - Methods and compositions are provided for evaluating a diabetic patient for treatment with an incretin-based therapy. In certain embodiments, evaluation is ongoing and the patient is evaluated at multiple times. In additional embodiments, a diabetic patient is treated with an incretin-based therapy after the patient has been evaluated for expression levels of GLP-1R in a biological sample. In some aspects, the biological sample is specifically a blood sample that has been enriched for peripheral blood monocytes. | 2014-04-17 |
20140107029 | Methods and Apparatus for Creating Particle Derivatives of HDL with Reduced Lipid Content - The present invention is directed to systems, apparatus and methods for creating derivatives of at least one form of HDL without substantially affecting LDL. These derivatives of HDL are particles with reduced lipid content, particularly reduced cholesterol content. These particles have the capacity to bind cholesterol and are administered to a patient to enhance cellular cholesterol efflux and reduce cholesterol levels in cells, tissues, organs, and blood vessels. The present method is useful for treating atherogenic vascular disease and may be combined with other therapies such as statins, inhibitors of cholesterol absorption, niacin, anti-inflammatories, exercise and dietary restriction. | 2014-04-17 |
20140107030 | POLYPEPTIDE COMPOUNDS FOR INHIBITING ANGIOGENESIS AND TUMOR GROWTH - In certain embodiments, this present invention provides polypeptide compositions, including compositions containing a modified polypeptide, and methods for inhibiting Ephrin B2 or EphB4 activity. In other embodiments, the present invention provides methods and compositions for treating cancer or for treating angiogenesis-associated diseases. | 2014-04-17 |
20140107031 | TEMPLATE-FIXED PEPTIDOMIMETICS - Template-fixed β-hairpin peptidomimetics of the general formula | 2014-04-17 |
20140107032 | Methods of Treating, Reducing the Incidence of, and/or Preventing Ischemic Events - Methods of treating, reducing the incidence of, and/or preventing an ischemic event in a patient undergoing percutaneous coronary intervention (PCI), comprising administering to the patient a pharmaceutical composition comprising cangrelor. The method may further comprise administering an additional therapeutic agent to the patient, the additional therapeutic agent comprising bivalirudin or a P2Y | 2014-04-17 |
20140107033 | METHODS FOR PREVENTION AND TREATMENT OF ACUTE RENAL INJURY - The disclosure relates to a method for protecting a kidney from renal injury. For example, acute renal injury may be associated with decreased or blocked blood flow in the subject's kidney or exposure to a nephrotoxic agent, such as a radiocontrast dye. The methods include administering to the subject an effective amount of an aromatic-cationic peptide to a subject in need thereof. | 2014-04-17 |
20140107034 | SOLUBLE HYBRID FCGAMMA RECEPTORS AND RELATED METHODS - Disclosed are soluble hybrid Fcγ receptor (FcγR) polypeptide compositions and related methods of using such polypeptides to treat IgG-mediated and immune complex-mediated inflammation. Also disclosed are related compositions and methods for producing the soluble hybrid FcγR polypeptides. | 2014-04-17 |
20140107035 | METHODS OF TREATING FIBROSING DISEASES BY INDUCTION OF IMMUNE TOLERANCE - The present invention has demonstrated for the first time that orally administered type I collagen (CI) induced tolerance to CI in patients suffering from systemic sclerosis (SSc) and ameliorated clinical manifestations of the disease. Accordingly, the present invention provides methods of treating a fibrosing disease by oral administration of a tissue protein, for example, collagen, derived from the tissue undergoing fibrosis. | 2014-04-17 |
20140107036 | Production and Delivery of a Stable Collagen - Improved methods are provided for the recombinant synthesis of collagen, particularly collagen VII, in host cell, and for therapeutic delivery of the same. The recombinant collagen is produced in a host cell that has increased levels of prolyl-4-hydroxylase, relative to basal cell levels. The collagen produced by the methods of the invention has increased numbers of modified proline residues, relative to a recombinant collagen produced in a host cell having basal levels of prolyl-4-hydroxylase. The increased proline modification provides for a collagen having increased stability, including increased in vivo stability. | 2014-04-17 |
20140107037 | METHODS OF TREATING ALZHEIMER'S DISEASE, HUNTINGTON'S DISEASE, AUTISM, OR OTHER DISORDERS - The disclosure relates, at least in part, to methods of treating autism in a patient in need thereof by administering an effective amount of a disclosed compound, e.g., a NMDA receptor glycine site partial agonist. | 2014-04-17 |
20140107038 | METHOD FOR ADMINISTERING OMEGA-CONOPEPTIDE - The present invention is directed to a method of producing analgesia in a mammalian subject. The method includes administering to the subject an omega conopeptide, preferably ziconotide, in combination with an analgesic selected from the group consisting of morphine, bupivacaine, clonidine, hydromorphone, baclofen, fentanyl 1, buprenorphine, and sufentanil, or its pharmaceutically acceptable salts thereof, wherein the ω-conopeptide retains its potency and is physically and chemically compatible with the analgesic compound. A preferred route of administration is intrathecal administration, particularly continuous intrathecal infusion. The present invention is also directed to a pharmaceutical formulation comprising an omega conopeptide, preferably ziconotide, an antioxidant, in combination with an analgesic selected from the group consisting of morphine, bupivacaine, clonidine, hydromorphone, baclofen, fentanyl, buprenorphine, and sufentanil. | 2014-04-17 |
20140107039 | POLYCOMB REPRESSIVE COMPLEX 2 (PRC2) INHIBITORS AND USES THEREOF - The present invention relates to Polycomb Repressive Complex 2 (PRC2) peptide inhibitors and their use for the treatment of cancer and other conditions associated with aberrant PRC2 methyltransferase activity. | 2014-04-17 |
20140107040 | SUBSTITUTED N-ARYL PYRIDINONES - Disclosed herein are substituted N-Aryl pyridinone fibrotic inhibitors and/or collagen infiltration modulators of Formula I, process of preparation thereof, pharmaceutical compositions thereof, and methods of use thereof. | 2014-04-17 |
20140107041 | KDR AND VEGF/KDR BINDING PEPTIDES AND THEIR USE IN DIAGNOSIS AND THERAPY - The present invention provides polypeptides, peptide dimer, and multimeric complexes comprising at least one binding moiety for KDR or VEGF/KDR complex, which have a variety of uses wherever treating, detecting, isolating or localizing angiogenesis is advantageous. Particularly disclosed are synthetic, isolated polypeptides capable of binding KDR or VEGF/KDR complex with high affinity (e.g., having a K | 2014-04-17 |
20140107042 | COMPOSITIONS, METHODS AND USES FOR RADIOPROTECTANTS - Embodiments herein report methods and compositions for treating or preventing adverse effects of radiation therapies. In certain embodiments, compositions and methods relate to reducing or inhibiting damage due to acute, periodic or chronic radiation exposure. | 2014-04-17 |
20140107043 | NEW CONJUGATED MOLECULES COMPRISING A PEPTIDE DERIVED FROM THE CD4 RECEPTOR COUPLED TO A POLYANIONIC POLYPEPTIDE FOR THE TREATMENT OF AIDS - This invention relates to a conjugated molecule comprising a peptide derived from the CD4 receptor coupled to an organic molecule by means of a linker as well as a process for its preparation. Said organic molecule comprises a 5 to 21 amino acid anionic polypeptide. Such a conjugated molecule can be used in antiviral treatment, namely in the treatment of AIDS. | 2014-04-17 |
20140107044 | SELECTIVE GLYCOSIDASE INHIBITORS AND USES THEREOF - The invention provides compounds for selectively inhibiting glycosidases, prodrugs of the compounds, and pharmaceutical compositions including the compounds or prodrugs of the compounds. The invention also provides methods of treating diseases and disorders related to deficiency or overexpression of O-GlcNAcase, accumulation or deficiency of O-GlcNAc. | 2014-04-17 |
20140107045 | METHOD FOR TREATMENT OF DISEASE WITH PURE PORCINE MONOSIALOGANGLIOSIDE GM1 - A process for preparing pure monosialoganglioside GM1 in the form of its sodium salt. There is provided a process for the isolation and purification of monosialoganglioside GM1 comprising (a) separation of GM1 from a lipidic mixture containing the monosialoganglioside GM1 as the main ganglioside component by ion exchange column-chromatography using an eluent comprising potassium or caesium ions, (b) recovery of the solute from the eluted solution, (c) diafiltration of an aqueous solution of the recovered solute, and (d) second diafiltration after the addition of 1 M NaCl, and recovering GM1. The purity level of GM1 obtained is higher than 99.0%. | 2014-04-17 |
20140107046 | COSMETIC COMPOSITIONS CONTAINING AT LEAST ONE FLAVONOID AND FERULIC ACID - The invention provides synergistic aqueous compositions comprising at least one flavonoid, and ferulic acid, and optionally one or more additional antioxidants, for cosmetic use. | 2014-04-17 |
20140107047 | COSMETIC COMPOSITIONS FOR INCREASING BIOAVAILABILITY OF ACTIVE COMPOUNDS - Aqueous compositions comprising a) at least one active compound and b) at least one hydrotrope in an amount effective to increase transdermal penetration of the active compound, and methods for increasing bioavailability of active compounds are provided. | 2014-04-17 |
20140107048 | COMPOSITIONS CONTAINING PHENOLIC COMPOUNDS AND HYDROTROPES FOR COSMETIC USE - Aqueous compositions comprising (a) at least one phenolic compound and (b) at least one hydrotrope in an amount effective to solubilize said at least one phenolic compound in water are provided for cosmetic and other uses. | 2014-04-17 |
20140107049 | MANNOSE DERIVATIVES FOR TREATING BACTERIAL INFECTIONS - The present invention relates to compounds useful for the treatment or prevention of bacteria infections. The invention also provides pharmaceutically acceptable compositions containing the compounds and methods of using the compositions in the treatment of bacteria infections. The invention also provides processes for making the compounds of the invention. | 2014-04-17 |
20140107050 | INCREASING BIOAVAILABILITY OF N-COUMAROYLDOPAMINE THROUGH CO-ADMINISTRATION WITH A CATECHOL-O-MEHTYLTRANSFERASE (COMT) INHIBITOR - The present invention is directed to a composition including N-Coumaroyldopamine and a catechol-o-methyltransferase (COMT) inhibitor for promoting weight loss in a user. | 2014-04-17 |
20140107051 | ISOFLAVONES FOR TREATING MUCOPOLYSACCHARIDOSES - A pharmaceutical composition including a pharmaceutically acceptable excipient; and a natural isoflavone of formula (I), a derivative thereof, or a pharmaceutically acceptable salt thereof, the natural isoflavone, the derivative thereof, or the pharmaceutically acceptable salt thereof being in a therapeutically effective amount for the treatment of mucopolysaccharidosis. A method of treatment of mucopolysaccharidosis, the method including administering to a patient in the need of such treatment—a therapeutically effective amount of a natural isoflavone of formula (I), a derivative thereof, or a pharmaceutically acceptable salt thereof. | 2014-04-17 |
20140107052 | EDIBLE COMPOSITION - Foods or meals high in available carbohydrate such as sucrose or starch increase postprandial blood glucose concentrations. Repeated high post-prandial plasma glucose “spikes” are associated with an increased risk of developing type II diabetes. Unregulated glycemic excursions are undesirable, and any reduction or “blunting” of the post-prandial glucose concentration in blood is potentially beneficial. This invention relates to an edible composition for delay of intestinal glucose uptake through synergistic inhibition of both active sodium glucose co-transporter 1 (SGLT1) and passive glucose transporter 2 (GLUT2) leading to flattening or blunting of the post-prandial glucose peak. Thus in a first aspect of the invention, an edible composition is provided, the composition comprising at least 5% dry weight at least one flavonoid aglycone and at least 5% dry weight at least one flavonoid glucoside, wherein the flavonoid glucoside is at least 20%, preferably at least 40%, most preferably at least 60% more resistant to hydrolysis by lactase phloridzin hydrolase than quercetin-4-glucoside, and wherein the flavonoid aglycone is a GLUT 2 inhibitor and the flavonoid glucoside is a SGLT 1 inhibitor. | 2014-04-17 |
20140107053 | APPLES WITH HIGH POLYPHENOLIC CONTENT - The invention relates to apples comprising high concentrations of polyphenols, to processes for obtaining said apples and to uses of apples as a method of treatment of prophylaxis of cardiovascular disease, colon cancer and digestive health. | 2014-04-17 |
20140107054 | Method of treating clostridium difficile-associated diarrhea - A method of treating a disease or disorder caused by the presence of a bacterium selected from the group consisting | 2014-04-17 |
20140107055 | METHOD FOR THE PROTECTION OF TREES - The present invention provides a method for the prevention/treatment of bark beetle and/or wood borer infestation of trees comprising treatment of the tree with a composition comprising a macroyclic lactone. | 2014-04-17 |
20140107056 | INSECTICIDAL COMPOUNDS - The present invention provides compounds of formula (I): wherein A | 2014-04-17 |
20140107057 | PESTICIDAL MIXTURES INCLUDING ISOXAZOLINE DERIVATIVES - The present invention provides a combination product comprising a component A and a component B, wherein component A is a compound of formula (I) wherein A | 2014-04-17 |
20140107058 | PHARMACEUTICAL COMPOSITIONS COMPRISING FORMS OF 5-AZACYTIDINE - The invention provides novel polymorphic and pseudopolymorphic crystalline forms of 5-azacyditine, along with methods for preparing said forms, wherein 5-azacytidine is represented by the formula: | 2014-04-17 |
20140107059 | COMPOSITIONS CONTAINING ADENOSINE OR AN ADENOSINE ANALOGUE AND HYDROTROPES FOR COSMETIC USE - The present invention provides aqueous compositions comprising (a) at least one compound selected from the group consisting of adenosine and adenosine analogues, and (b) at least one hydrotrope in an amount effective to solubilize said at least one compound (a) in water, for cosmetic uses. | 2014-04-17 |
20140107060 | Fused Pentacyclic Polyethers - Disclosed are polycyclic polyether compounds of formula I and pharmaceutical compositions comprising such compounds. | 2014-04-17 |
20140107061 | NOVEL STRAINS OF STREPTOMYCES MICROFLAVUS AND METHODS OF THEIR USE TO CONTROL PLANT DISEASES AND PESTS - The present invention relates to novel strains of | 2014-04-17 |
20140107062 | COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING DISEASES OF BODY PASSAGEWAYS - The present invention provides compositions and methods for treating or preventing diseases associated with vascular and non-vascular body passageways, the method comprising the step of delivering to a body passageway a therapeutic agent delivered locally through a polymer matrix from an implanted stent or other structure. | 2014-04-17 |
20140107063 | OSTEOARTHRITIS DIET FORMULATIONS - Dietary formulations and methods for treating, preventing or delay onset of osteoarthritis in canines and other animals are disclosed. The formulations are enriched in n-3 fatty acids and limited in n-6 fatty acids. | 2014-04-17 |
20140107064 | GLYCOSAMINOGLYCAN ORAL USE AND COMPOSITIONS - The present invention concerns the use of a glycosaminoglycan association of hyaluronic acid and chondroitin sulfate for the preparation of oral compositions for the prevention or for the treatment of upper gastro-intestinal tract disorders and for the preparation of upper gastro-intestinal epithelial damage, as well as the oral compositions comprising said glycosaminoglycan association. | 2014-04-17 |
20140107065 | Biopolymer System for Tissue Sealing - A tissue sealant for use in surgical and medical procedures for sealing the tissues of a living mammal is provided. The tissue sealant comprises a hydrogel which is formed by gelation of a premix disposed on the tissue to be sealed. The premix comprises alkylated chitosan or a gelatin, and a polybasic carboxylic acid or an oxidized polysaccharide, in an aqueous medium. The premix can also include a dehydrating reagent, a carboxyl activating reagent, or both. A specific use of the tissue sealant is in the repair of the dura mater after brain surgery to prevent leakage of cerebrospinal fluid. The tissue sealant may include a therapeutic or protective agent such as an antibiotic or an anti-inflammatory drug. | 2014-04-17 |
20140107066 | HIGH MOLECULAR WEIGHT HEPAROSAN POLYMERS AND METHODS OF PRODUCTION AND USE THEREOF - High molecular weight heparosan polymers are described, as are methods of producing and using the high molecular weight heparosan polymers. | 2014-04-17 |
20140107067 | COMPOSITIONS COMPRISING DIETARY FAT COMPLEXERS AND METHODS FOR THEIR USE - This invention relates to fat containing consumable food products comprising α-cyclodextrin. The food products have reduced levels of bioavailable fat but have substantially the same fat, cholesterol and caloric content as a like food without α-cyclodextrin. The invention also relates to methods for reducing the bioavailability of fats in fat containing food products without reducing caloric intake as determined by bomb calorimetry and to methods for increasing high density lipoproteins in a subject and reducing or controlling weight by administering the food products of this invention. | 2014-04-17 |
20140107068 | MARKER FOR DETERMINATION OF SENSITIVITY TO ANTICANCER AGENT - A marker can determine whether or not a patient has a therapeutic response to an anti-cancer agent. A novel cancer therapy employs the marker. The marker can be N-acetylglucosamine, an amino-acid-metabolism-related substance, a nucleic-acid-metabolism-related substance, a substance in the pentose phosphate pathway, a substance in the glycolytic pathway, a substance in the TCA cycle, a polyamine-metabolism-related substance, lauric acid, 6-phosphogluconic acid, butyric acid, 4-methylpyrazole, isobutylamine, glycolic acid, NADH, NAD | 2014-04-17 |
20140107069 | PLANT TREATMENT METHOD - A plant treatment method comprising contacting the plant with: (a) a compound of formula (I): or a derivative salt thereof wherein L is a linking group; each of R | 2014-04-17 |
20140107070 | PARAFFINIC OIL-IN-WATER EMULSIONS FOR CONTROLLING INFECTION OF CROP PLANTS BY FUNGAL PATHOGENS - This disclosure features fungicidal combinations that include a paraffinic oil and an emulsifier. The combinations can further include one or more of the following: pigments, silicone surfactants, anti-settling agents, conventional fungicides such as demethylation inhibitors (DMI) and quinone outside inhibitors (Qol) and water. The fungicidal combinations are used for controlling infection of a crop plant by a fungal pathogen. | 2014-04-17 |
20140107071 | METHODS OF MANUFACTURING TOPICAL COMPOSITIONS AND APPARATUS FOR THE SAME - Provided according to some embodiments of the invention are methods of manufacturing a pharmaceutical composition. In some embodiments, such methods include homogenizing at a first excipient composition that includes a viscosity agent and at least one solvent to form a first premix composition; separately homogenizing at least one active pharmaceutical ingredient (API) and a second excipient composition to form a second premix composition; and combining the first premix composition and the second premix composition to form the composition. The pre-mixing of constituents may increase the stability of the API and provide uniformity of the dispersion of the constituents throughout the final topical composition. | 2014-04-17 |
20140107072 | New Method For Making Krill Meal - A new method for krill meal production has been developed using a two step cooking process. In the first step the proteins and phospholipids are removed from the krill and precipitated as a coagulum. In the second stage the krill without phospholipids are cooked. Following this, residual fat and astaxanthin are removed from the krill using mechanical separation methods. A novel krill meal product with superior nutritional and technical properties is prepared. | 2014-04-17 |
20140107073 | GDF-8 Inhibitors - Described are GCF-8 inhibitors of the formula (I), | 2014-04-17 |
20140107074 | COMPOUNDS AND METHODS FOR INHIBITING NHE-MEDIATED ANTIPORT IN THE TREATMENT OF DISORDERS ASSOCIATED WITH FLUID RETENTION OR SALT OVERLOAD AND GASTROINTESTINAL TRACT DISORDERS - The present disclosure is directed to compounds of the structure (X): | 2014-04-17 |
20140107075 | NOVEL COMPOUNDS AS RECEPTOR MODULATORS WITH THERAPEUTIC UTILITY - The present invention relates to novel amine derivatives, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals as modulators of sphingosine-1-phosphate receptors. | 2014-04-17 |
20140107076 | CRYSTALLIZATION METHOD AND BIOAVAILABILITY - Preparation, in-vitro and in vivo characterization of novel forms of (1-hydroxy-2-imidazol-1-yl-1-phosphono-ethyl)phosphonic acid, suitable for pharmaceutical compositions in drug delivery systems for humans. | 2014-04-17 |
20140107077 | TRIPTOLIDE PRODRUGS - The invention provides compounds of formula I: | 2014-04-17 |
20140107078 | HYPOPHOSPHOROUS ACID DERIVATIVES HAVING ANTIHYPERALGIC ACTIVITY AND BIOLOGICAL APPLICATIONS THEREOF - The invention relates to hypophosphorous acid derivatives of formula (I) wherein —X is H or OH, —R represents one or several radicals R | 2014-04-17 |
20140107079 | Beta-hydroxy-gamma-aminophosphonates for Treating Immune Disorders - The present disclosure provides methods of treating, ameliorating, or preventing immune disorders, allergic disorders, or inflammatory disorders, or combinations thereof, or providing hepatoprotection in subject. In one aspect, the method comprises administering to a subject a therapeutically effective amount of a β-hydroxy-γ-aminophosphonate or β-amino-γ-aminophosphonate. | 2014-04-17 |
20140107080 | BRAIN FUNCTION IMPROVING AGENT - Brain function improving agents, cognitive judgment ability improving agents, as well as foods and beverages that contain krill oil as an active ingredient are provided. | 2014-04-17 |
20140107081 | SALICYLIC ACID TOPICAL FORMULATION - Topical skin treatment formulation containing salicylic acid or a derivative thereof, dissolved in a solvent system comprising (i) dimethyl isosorbide; (ii) a C1 to C9 alkyl salicylate; and (iii) a glyceryl fatty acid ester. The solvent system may also comprise an alcohol, a polyoxyalkylene-based solvent, and/or a C1 to C4 alkyl glucose ester. The formulation may be used in the treatment of acne. The solvent system improves the targeted delivery of the salicylic acid or derivative to relevant sites on the skin. | 2014-04-17 |
20140107082 | Method and Compositions for Treating Psoriasis - Method and composition for treating psoriasis and other skin disorders. | 2014-04-17 |
20140107083 | TREATMENT OF CONGESTION USING STEROIDS AND ADRENERGICS - A decongestant composition is provided comprising: (a) a safe and effective amount of an adrenergic compound; (b) a safe and effective amount of a steroid; and (c) a pharmaceutically-acceptable carrier. Methods of treating congestion in a human or animal subject are also provided comprising administering to the subject a composition comprising: (a) an adrenergic compound; and (b) a steroid; where the daily dose of the adrenergic compound administered to the subject is from about 1 μg to about 800 μg, and the daily dose of the steroid administered to the subject is from about 1 μg to about 400 μg. | 2014-04-17 |
20140107084 | ULTRA LOW DOSE DOXEPIN AND METHODS OF USING THE SAME TO TREAT SLEEP DISORDERS - The invention relates to doxepin, pharmaceutically acceptable salts and prodrugs of doxepin; compositions containing the same, and the use of any of the aforementioned for the treatment of sleep disorders. | 2014-04-17 |
20140107085 | Bifunctional AKR1C3 Inhibitors/Androgen Receptor Modulators and Methods of Use Thereof - The invention includes compositions comprising selective AKR1C3 inhibitors. The invention also includes compositions comprising bifunctional AKR1C3 inhibitors and selective androgen receptor modulators. The invention further includes methods of treatment using the compositions of the invention. | 2014-04-17 |
20140107086 | System and Method for Diagnosis and Treatment - This invention relates to a low cost rapid response diagnostic system to determine cortisol levels in patients selected as potential candidates for GCR (glucocorticoid receptor) antagonist therapy utilizing a GCR antagonist, such as ORG 34517. The rapid, sensitive, and inexpensive test can be used to determine patients who have non-normal cortisol production or disordered circadian rhythms as a method for selecting subjects for GCR antagonist therapy for whom it is likely to have beneficial and/or therapeutic effects, and can also be used to monitor changes in cortisol levels in response to treatment. | 2014-04-17 |
20140107087 | Methods, Compounds and Pharmaceutical Compositions for Treating Anxiety and Mood Disorders - Pharmaceutical compositions containing a cocktail of inhibitors of central stress nuclei are provided. The pharmaceutical compositions are useful for the prevention and treatment of a variety of conditions in mammals including humans, including anxiety and mood disorders such as depression. | 2014-04-17 |
20140107088 | MEDICAL DEVICES AND METHODS COMPRISING AN ANABOLIC AGENT FOR TREATMENT OF AN INJURY - Improved medical devices and methods are provided comprising an anabolic agent for healing an injury. These improved medical devices and methods can enhance healing in injuries from traumatic soft tissue injury, surgical injuries, burn, traumatic brain injuries, musculotendinous injuries, musculoskeletal conditions, bone injury or other injuries or maladies, which can be chronic or non-chronic in origin. In some embodiments, the medical device comprises a drug depot that releases the anabolic agent over at least 2 days to enhance healing of an injury. | 2014-04-17 |
20140107089 | STRUCTURAL MODIFICATION OF 19-NORPROGESTERONE I: 17-ALPHA-SUBSTITUTED-11-BETA-SUBSTITUTED-4-ARYL AND 21-SUBSTITUTED 19-NORPREGNADIENEDIONE AS NEW ANTIPROGESTATIONAL AGENTS - Disclosed are compounds having the general formula: | 2014-04-17 |
20140107090 | TREATMENT AND PREVENTION OF MASTITIS - Treating and Preventing mastitis employing cationic steroidal antimicrobials (CSAs). Treating or preventing clinical mastitis in a mammal includes administering a cationic steroidal anti-microbial compound (CSA) formulation to the intra-mammary organ of a mammal (e.g., a dairy cow), such as by injection into the mammary organ (e.g., through the teat of the mammary organ), and/or topical application. The dairy cow can be lactating and have a somatic cell count (SCC) less than or equal to 500,000 cells/mL at the time of administering the CSA formulation. Alternatively, the dairy cow can be lactating and have a somatic cell count (SCC) greater than 500,000 cells/mL at the time of administering the CSA formulation. The dairy cow can be taken out of production during the administration of the CSA formulation for a period of time of about 3 days or less, 2 days or less, or 1 day or less. | 2014-04-17 |
20140107091 | PROCESS FOR THE PRODUCTION OF ESTETROL INTERMEDIATES - The present invention relates to a process for the preparation of a compound of formula (I) comprising the steps of a) reacting a compound of formula (II) with a silylating or an acylating agent to produce compound of formula (III), wherein P | 2014-04-17 |
20140107092 | BACTERIAL ETIOLOGY OF COLORECTAL CANCER - Methods for predicting risk of developing colorectal cancer, for treating colorectal cancer, and reducing risk of developing colorectal cancer. | 2014-04-17 |
20140107093 | COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE - The present invention relates to compounds useful as inhibitors of ATR protein kinase. The invention also relates to pharmaceutically acceptable compositions comprising the compounds of this invention; methods of treating of various diseases, disorders, and conditions using the compounds of this invention; processes for preparing the compounds of this invention; intermediates for the preparation of the compounds of this invention; and methods of using the compounds in in vitro applications, such as the study of kinases in biological and pathological phenomena; the study of intracellular signal transduction pathways mediated by such kinases; and the comparative evaluation of new kinase inhibitors. | 2014-04-17 |
20140107094 | METHYLENE LINKED QUINOLINYL MODULATORS OF RORyt - The present invention comprises compounds of Formula I. | 2014-04-17 |
20140107095 | ESTROGEN RECEPTOR MODULATORS AND USES THEREOF - Described herein are compounds that are estrogen receptor modulators. Also described are pharmaceutical compositions and medicaments that include the compounds described herein, as well as methods of using such estrogen receptor modulators, alone and in combination with other compounds, for treating diseases or conditions that are mediated or dependent upon estrogen receptors. | 2014-04-17 |
20140107096 | HETEROARYL LINKED QUINOLINYL MODULATORS OF RORyt - The present invention comprises compounds of Formula I. | 2014-04-17 |
20140107097 | HETEROARYL LINKED QUINOLINYL MODULATORS OF RORyt - The present invention comprises compounds of Formula I. | 2014-04-17 |
20140107098 | IMIDAZOLO-, OXAZOLO-, AND THIAZOLOPYRIMIDINE MODULATORS OF TRPV1 - Certain TRPV1-modulating imidazolo-, oxazolo-, and thiazolopyrimdine compounds are described. The compounds may be used in pharmaceutical compositions and methods for treating disease states, disorders, and conditions mediated by TRPV1 activity, such as pain, arthritis, itch, cough, asthma, or inflammatory bowel disease. | 2014-04-17 |
20140107099 | PYRAZOLOPYRIMIDINE JAK INHIBITOR COMPOUNDS AND METHODS - The invention provides JAK kinase inhibitors of Formula Ia, enantiomers, diasteriomers or pharmaceutically acceptable salts thereof, wherein R | 2014-04-17 |
20140107100 | Benzoxazepines as Inhibitors of PI3K/mTOR and Methods of Their Use and Manufacture | 2014-04-17 |
20140107101 | Macrocyclic Indole Derivatives Useful as Hepatitis C Virus Inhibitors - Inhibitors of HCV replication of formula (I) | 2014-04-17 |
20140107102 | Ocular Allergy Treatments - Compositions, kits and methods for the treatment or prevention of ocular allergies and inflammation and the symptoms thereof comprising alcaftadine or a pharmaceutically acceptable salt thereof. | 2014-04-17 |
20140107103 | HETEROCYCLE-SUBSTITUTED PIPERAZINO-DIHYDROTHIENOPYRIMIDINES - Dihydrothienopyrimidinesulphoxides of formula 1 | 2014-04-17 |
20140107104 | COMBINATION MEDICINE FOR TREATMENT OF DEPRESSION - The present invention provides a combination medicine for treatment of depression, comprising a combination of (A1) an antidepressant and either (B1) a dopamine D1 receptor agonist or (C1) a dopamine D1 receptor antagonist; and a method for screening for an antidepressant that in combination with a dopamine D1 receptor agonist provides an improvement in treatment of depression, the method comprising the steps of: administering, to a mammal, (A2) a compound having an antidepressant action and (B1) a dopamine D1 receptor agonist, and detecting a greater increase in depression-related gene expression, dopamine D1 receptor expression and/or dopamine D1 receptor signaling in comparison with the case where (A2) the compound having an antidepressant action or (B1) the dopamine D1 receptor agonist is administered. | 2014-04-17 |
20140107105 | SUBSTITUTED PYRIDYL AMIDE COMPOUNDS AS MODULATORS OF THE HISTAMINE H3 RECEPTOR - Certain substituted pyridyl amide compounds are histamine H | 2014-04-17 |
20140107106 | THERAPEUTIC AGENTS, AND METHODS OF MAKING AND USING THE SAME - In part, the present invention is directed to antibacterial compounds. | 2014-04-17 |
20140107107 | PHARMACEUTICAL FORMULATION CONTAINING THIENOTRIAZOLODIAZEPINE COMPOUNDS - A solid dispersion comprising an amorphous thienotriazolodiazepine compound of the Formula ( | 2014-04-17 |
20140107108 | COMPOSITIONS COMPRISING ALPRAZOLAM FOR TREATING PRIMARY INSOMNIA AND INSOMNIA ASSOCIATED WITH ANXIETY STATES AND PROCESS FOR PREPARING THEM - Disclosed is a composition comprising alprazolam for treating primary insomnia and insomnia associated with anxiety states and the corresponding use and method comprising the administration of alprazolam sublingual tablets having a disintegration time lower than 30 seconds and having the alprazolam preferably in non-crystalline or partially crystalline form according to the X-ray diffraction crystallography expanded for the position delta 9-12.5 (2 theta), to a patient suffering from said disorder. There is also disclosed a method for preparing a composition according to the invention, where the alprazolam is solved in a pharmaceutical acceptable solvent and a binder, preferably polyvinylpyrrolidone, is incorporated to the solution. A pre-made mixture of part of the cross-linked carboxymethyl-cellulose and the rest of the ingredients of the composition is impregnated with the solution and is dried and grinded, and is added to the rest of the cross-linked carboxymethyl-cellulose and the flavoring additives, being then mixed and compressed. | 2014-04-17 |
20140107109 | AMINO-DIHYDROTHIAZINE AND AMINO-DIOXIDO DIHYDROTHIAZINE COMPOUNDS AS BETA-SECRETASE ANTAGONISTS AND METHODS OF USE - The present invention provides a new class of compounds useful for the modulation of beta-secretase enzyme (BACE) activity. The compounds have a general Formula I: | 2014-04-17 |
20140107110 | ANTI-FIBROTIC PYRIDINONES - Disclosed are pyridinone compounds, method for preparing these compounds, and methods for treating fibrotic disorders. | 2014-04-17 |
20140107111 | USE OF SIGMA LIGANDS IN DIABETES TYPE-2 ASSOCIATED PAIN - The invention refers to the use of a sigma ligand, particularly a sigma ligand of formula (I) to prevent and/or treat type-2 diabetes-associated pain and related symptoms. | 2014-04-17 |
20140107112 | Agents for Combating Plant Pests - The present invention relates to compositions for controlling plant pests, which contain the compound of the formula (I) | 2014-04-17 |
20140107113 | PHARMACEUTICAL COMPOSITION COMPRISING A TRPA1 ANTAGONIST AND A BETA-2 AGONIST - The present patent application relates to a pharmaceutical composition comprising a transient receptor potential ankyrin-1 receptor (“TRPA1”) antagonist and a beta-2 adrenergic receptor agonist (“beta-2 agonist”). | 2014-04-17 |
20140107114 | Combination Therapy Comprising A CDK4/6 Inhibitor and a P13K Inhibitor for Use in the Treatment of Cancer - A combination of a CDK4/6 inhibitor and a P3Kinase inhibitor for the treatment of cancer. | 2014-04-17 |
20140107115 | NOVEL IMMUNE SYSTEM MODULATORS - The present invention relates to a compound of Formula I: or a pharmaceutically acceptable salt thereof, wherein the symbols are as defined in the specification; a pharmaceutical composition comprising the same; and a method for treating or preventing autoimmunity disease using the same. | 2014-04-17 |